Ultra High-Throughput Assays on Live Microorganisms
Using microfluidics, we replace traditional growth devices, such as Petri dishes or microtiter plates with 1nl to 1pl droplets of culture medium. Stable for several weeks, they act like microscopic culture vessels. Thanks to patented technologies, Biomillennia can cultivate and undertake functional assays on the droplets: mixing, adding reagents, merging, incubating, screening and much more. The difference is the throughput. With traditional lab techniques, it would take 120 days to generate 10 million microtiter plates. Biomillenia generates this number of microtiter plates, and screens them, one by one, in less than 3 hours.
Our platform integrates culturomics and supports multiple growth conditions (aerobic, anaerobic or microaerophilic), incubation temperatures or use of up to 60 different types of cell culture medium. The synergy of state-of-the-art culturomics and microfluidics enables Biomillenia to cultivate previously “unculturable” microbes. Droplets create ideal conditions for growth, under which slower growing or fastidious microbes can thrive. Our data show that droplets capture 80% of the original diversity of a microbiota sample, compared to 20% for microtiter plates.
Our platform streamlines, for example, cell-banking processes:
Incorporation in droplet of single bacteria
Strain growth, assay, and strain selection
Strain isolation and growth
A variety of other assay capabilities allow direct selection of many desired phenotypes, using non- GMO techniques.
Novel Beneficial Strains
Biomillenia has the know-how to culture and undertake functional analysis of microbes in low volume droplets using the Company’s proprietary lab-on-a-chip platform.
A key advantage of the platform is that it maintains a higher diversity of the original microbe sample; thus enabling Biomillenia to culture previously ‘unculturable’ microbes.
With a parallel throughput several magnitudes higher than conventional methods (>30,000,000 bacteria strains per day), Biomillenia can culture and screen live strains and variants for next-generation therapeutics and consumer health products in volumes that to date have not been economically feasible.
Microbial strains with improved desired phenotype
- Ultra-high-throughput single cell culture and screening allows for the processing of tens of millions of variants in a single screen
- Workflows can be repeated in rapid (weeks) turnaround time
- A variety of assay capabilities allow direct selection of many desired phenotypes using non-GMO techniques
Tel: +33 1 48 91 02 82
BIOMILLENIA SAS, 102 Avenue Gaston Roussel
c/o BIOCITECH, Building Lavoisier
93230 Romainville, France